Luteolin suppresses lung cancer progression through targeting the circ_0000190/miR-130a-3p/notch-1 signaling pathway

Zheng, Hao; Zhu, Xiaoyu; Gong, Enhui; Lv, Yuankai; Li, Yuling; Cai, Xiaoping

doi:10.1080/1120009x.2022.2102303

Cited by 10 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, β-sitosterol (YD1) has been studied for its potential antitumor and immunomodulatory effects . Additionally, luteolin (YD2), another component of Yadanzi oil emulsion, has been reported to possess anti-inflammatory, antioxidant, and immunostimulatory properties . Although the anticancer activity of B.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Study on the Mechanism of Yadanzi Oil in Treating Lung Cancer Based on Network Pharmacology and Molecular Docking Technology

Liu,

Shen,

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Brucea javanica oil emulsion (BJOE) is a compound Chinese medicine used for treating various cancers, such as lung cancer. However, the exact mechanism of its antilung cancer active ingredient remains unclear. This study aims to explore and validate the effective active ingredients and mechanism of action of BJOE in the treatment of lung cancer through network pharmacology, molecular docking technology, and cell experiments. The results showed that there were 13 active ingredients, 136 target genes, and 42 disease target-coexpressed genes in BJOE. The molecular docking results indicated that the main active components of the oil emulsion, YD1 (β-sitosterol), YD2 (luteolin), and YD3 (bruceitol), could stably bind to TP53 and MAPK1. Furthermore, the commercially available β-sitosterol luteolin was used as a representative compound to conduct cell experiments to verify its anticancer activity and mechanism. It was found that luteolin can inhibit the proliferation better than β-sitosterol and the activity of lung cancer cells by regulating the expression of related proteins through the P53/MAPK1 signaling pathway. This study combines network pharmacology prediction with experiments to demonstrate the "multicomponent, multitarget, multipathway" approach of B. javanica oil emulsion in treating lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

“… 21 Additionally, luteolin (YD2), another component of Yadanzi oil emulsion, has been reported to possess anti-inflammatory, antioxidant, and immunostimulatory properties. 22 Although the anticancer activity of B. javanica and its compounds has been extensively investigated, a precise mechanism of action is required.…”

Section: Discussionmentioning

confidence: 99%

Study on the Mechanism of Yadanzi Oil in Treating Lung Cancer Based on Network Pharmacology and Molecular Docking Technology

Liu,

Shen,

et al. 2024

ACS Omega

View full text Add to dashboard Cite

show abstract

“…Apart from the regulation of miRNAs by Luteolin in lung cancer, Zheng et al 2022 reported that Luteolin could regulate the circular RNAs (circRNAs), specifically circ_0000190, which was found to be upregulated in lung cancer tissues [ 75 ]. In their study, they discovered that Luteolin inhibited the viability, colony formation, migration, invasion, and induced apoptosis of lung cancer cells, and the overexpression of circ_0000190 was able to counteract the role of Luteolin in the suppression of lung cancer development [ 75 ]. Moreover, in the same study, circ_0000190 was shown to be directly bound with miR-130a-3p.…”

Section: Anticancer Properties Of Luteolin On Different Cancersmentioning

confidence: 99%

“…Moreover, in the same study, circ_0000190 was shown to be directly bound with miR-130a-3p. The study revealed that Luteolin suppressed the growth of lung cancer cells, metastasis, and Notch-1 signaling pathway by regulating the circ_0000190/miR-130a-3p axis in vitro and by regulating circ_0000190, Luteolin suppressed the tumor growth of lung cancer in vivo [ 75 ].…”

Section: Anticancer Properties Of Luteolin On Different Cancersmentioning

confidence: 99%

Therapeutic Potential of Luteolin on Cancer

Çetinkaya

Baran

2023

Vaccines

View full text Add to dashboard Cite

Cancer is a global concern, as the rate of incidence is increasing each year. The challenges related to the current chemotherapy drugs, such as the concerns related to toxicity, turn to cancer therapeutic research to discover alternative therapy strategies that are less toxic to normal cells. Among those studies, the use of flavonoids—natural compounds produced by plants as secondary metabolites for cancer therapy—has been a hot topic in cancer treatment. Luteolin, a flavonoid that has been present in many fruits, vegetables, and herbs, has been identified to exhibit numerous biological activities, including anti-inflammatory, antidiabetic, and anticancer properties. The anticancer property of Luteolin has been extensively researched in many cancer types and has been related to its ability to inhibit tumor growth by targeting cellular processes such as apoptosis, angiogenesis, migration, and cell cycle progression. It achieves this by interacting with various signaling pathways and proteins. In the current review, the molecular targets of Luteolin as it exerts its anticancer properties, the combination therapy that includes Luteolin with other flavonoids or chemotherapeutic drugs, and the nanodelivery strategies for Luteolin are described for several cancer types.

show abstract

“…Coincidentally, luteolin induced lung cancer cell apoptosis and Notch‐1 signaling pathway through modulating the circ_0000190/miR‐130a‐3p in vitro. Further research indicated that it subsided tumor growth in vivo by regulating circ_0000190, which offers a prospective therapeutic target for lung cancer (Zheng et al, 2022).…”

Section: Therapeutic Actions In Cancermentioning

confidence: 99%

Luteolin, a flavone ingredient: Anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researches

Shi,

Chen,

Gong

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

Current pharmaceutical research is energetically excavating the pharmacotherapeutic role of herb‐derived ingredients in multiple malignancies’ targeting. Luteolin is one of the major phytochemical components that exist in various traditional Chinese medicine or medical herbs. Mounting evidence reveals that this phytoconstituent endows prominent therapeutic actions on diverse malignancies, with the underlying mechanisms, combined medication strategy, and pharmacokinetics elusive. Additionally, the clinical trial and pharmaceutical investigation of luteolin remain to be systematically delineated. The present review aimed to comprehensively summarize the updated information with regard to the anticancer mechanism, combined medication strategies, pharmacokinetics, clinical trials, and pharmaceutical researches of luteolin. The survey corroborates that luteolin executes multiple anticancer effects mainly by dampening proliferation and invasion, spurring apoptosis, intercepting cell cycle, regulating autophagy and immune, inhibiting inflammatory response, inducing ferroptosis, and pyroptosis, as well as epigenetic modification, and so on. Luteolin can be applied in combination with numerous clinical anticarcinogens and natural ingredients to synergistically enhance the therapeutic efficacy of malignancies while reducing adverse reactions. For pharmacokinetics, luteolin has an unfavorable oral bioavailability, it mainly persists in plasma as glucuronides and sulfate‐conjugates after being metabolized, and is regarded as potent inhibitors of OATP1B1 and OATP2B1, which may be messed with the pharmacokinetic interactions of miscellaneous bioactive substances in vivo. Besides, pharmaceutical innovation of luteolin with leading‐edge drug delivery systems such as host–guest complexes, nanoparticles, liposomes, nanoemulsion, microspheres, and hydrogels are beneficial to the exploitation of luteolin‐based products. Moreover, some registered clinical trials on luteolin are being carried out, yet clinical research on anticancer effects should be continuously promoted.

show abstract

Luteolin suppresses lung cancer progression through targeting the circ_0000190/miR-130a-3p/notch-1 signaling pathway

Cited by 10 publications

References 39 publications

Study on the Mechanism of Yadanzi Oil in Treating Lung Cancer Based on Network Pharmacology and Molecular Docking Technology

Study on the Mechanism of Yadanzi Oil in Treating Lung Cancer Based on Network Pharmacology and Molecular Docking Technology

Therapeutic Potential of Luteolin on Cancer

Luteolin, a flavone ingredient: Anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researches

Contact Info

Product

Resources

About